[ad_1] Herantis Pharma Plc, Press Release, 25 October 2021 at 9:00 EEST Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of industry leaders in CNS and neurodegenerative diseases, chaired by Dr. Anders Gersel Pedersen (as announcment September 14, 2021).